Why calpain inhibitors are interesting leading compounds to search for new therapeutic options to treat leishmaniasis?

dc.creatorVidal, Vitor Ennes
dc.creatorMenna-Barreto, Rubem Figueiredo Sadock
dc.creatorBranquinha, Marta Helena
dc.creatorSantos, André Luis Souza dos
dc.creatord`Avila-Levy, Claudia M.
dc.date2017-03-28T12:18:40Z
dc.date2017-03-28T12:18:40Z
dc.date2017
dc.date.accessioned2023-09-26T22:24:46Z
dc.date.available2023-09-26T22:24:46Z
dc.identifierVIDAL, Vitor Ennes; et al. Why calpain inhibitors are interesting leading compounds to search for new therapeutic options to treat leishmaniasis?. Parasitology, v.114, n.2, p.117-123, Feb. 2017.
dc.identifier0031-1820
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/18182
dc.identifier10.1017/S003118201600189X
dc.identifier1469-8161
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8878905
dc.descriptionLeishmaniasis is a neglected disease, which needs improvements in drug development, mainly due to the toxicity, parasite resistance and low compliance of patients to treatment. Therefore, the development of new chemotherapeutic compounds is an urgent need. This opinion article will briefly highlight the feasible use of calpain inhibitors as leading compounds to search for new therapeutic options to treat leishmaniasis. The milestone of this approach is to take advantage on the myriad of inhibitors developed against calpains, some of which are in advanced clinical trials. The deregulated activity of these enzymes is associated with several pathologies, such as strokes, diabetes and Parkinson's disease, to name a few. In Leishmania, calpain upregulation has been associated to drug resistance and virulence. Whereas the difficulties in developing new drugs for neglected diseases are more economical than biotechnological, repurposing approach with compounds already approved for clinical use by the regulatory agencies can be an interesting shortcut to a successful chemotherapeutic treatment for leishmaniasis.
dc.description2030-01-01
dc.formatapplication/pdf
dc.languageeng
dc.publisherCambridge University Press
dc.rightsrestricted access
dc.subjectLeishmaniose
dc.subjectInibidores de calpaína
dc.subjectAbordagem de reorientação
dc.subjectCalpain inhibitors
dc.subjectleishmaniasis
dc.subjectrepurpose approach
dc.subjectMDL28170
dc.titleWhy calpain inhibitors are interesting leading compounds to search for new therapeutic options to treat leishmaniasis?
dc.typeArticle


Este ítem pertenece a la siguiente institución